RxDoctor Payments DataLook up a doctor →

David Bulbin, DO

Rheumatology · Danville, PANPI 1659679959

Payments from drug & device makers

$404,135in general payments, 2019–2025

Across 551 payments — averaging $733.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$125K
  • AstraZeneca$124K
  • AbbVie$78K
  • Novartis$31K
  • Sanofi$21K
  • GSK$21K
  • plus $4K from 11 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)156$124,830
AstraZeneca(2 entities)120$123,863
AbbVie117$78,125
Novartis93$31,418
Sanofi23$21,083
GSK21$20,512
Exo Imaging, Inc.2$3,550
Johnson & Johnson3$140
UCB, Inc.5$133
Sobi, Inc1$120
E.r. Squibb & Sons, L.L.C.1$113
Lilly USA, LLC1$74
Organon2$56
Aurinia Pharma U.S., Inc.2$43
Boehringer Ingelheim2$36
Genentech USA, Inc.1$26
Pfizer1$15

How this compares

$404,135 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$37,016
Medicare patients
251
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Danville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →